To confirm its selection, both a literature review and bioinformatic analysis were conducted, which revealed that RRM2 overexpression in HCC was consistently correlated with tumor growth, drug resistance, low survival rates and tumor aggressiveness (Chen et al. 2021; Kitab and Tsukiyama-Kohara 2023b; Qin et al. 2023; Tan et al. 2022; Yang et al. 2020a, b). The gene discussed is RRM2; the disease is hepatocellular carcinoma.